Levy Jerrold H
Duke University School of Medicine, Divisions of Cardiothoracic Anesthesiology and Critical Care, Duke University Hospital, 2301 Erwin Road, Durham, NC 27710, USA.
Clin Lab Med. 2014 Sep;34(3):443-52. doi: 10.1016/j.cll.2014.06.003. Epub 2014 Jul 30.
New oral anticoagulants (NOACs) are increasingly replacing vitamin K antagonists and older parenteral agents in clinical practice. NOACs offer several advantages compared with standard agents, including rapid onset of action, fixed dosing, and no requirement for routine coagulation monitoring. However, like all anticoagulants, NOACs carry a risk of bleeding. Here, we discuss the pharmacology and safety of NOACs, with particular emphasis on the risks of bleeding associated with NOACs versus standard anticoagulants, and we provide an overview of current bleeding management strategies.
新型口服抗凝药（NOACs）在临床实践中越来越多地取代维生素K拮抗剂和传统肠外抗凝药。与标准药物相比，NOACs具有多个优势，包括起效迅速、固定剂量以及无需常规凝血监测。然而，与所有抗凝药一样，NOACs有出血风险。在此，我们讨论NOACs的药理学和安全性，特别强调NOACs与标准抗凝药相比的出血风险，并概述当前的出血管理策略。
Zotero 插件